U/REGULATI

Regulation & FDA

12 filings logged

FDA, EMA and global regulators — approvals, complete response letters, advisory committees, guidance and policy.

Unit log

  1. V-5532

    FDA approves perioperative Imfinzi-Padcev regimen in bladder cancer

  2. P-9899

    FDA rejects ivonescimab in Summit’s EGFR-NSCLC application

  3. K-5457

    Nelkarmi wins accelerated FDA approval; GSK shares hold at GBX1,871

  4. C-6506

    FDA approves GSK’s Nelkarmi for pretreated ALK-positive lung cancer

  5. K-7275

    FDA Clears Cosentyx for Polymyalgia Rheumatica, Roche's Wilserdly for ESR1-Mutated Breast Cancer

  6. C-9698

    FDA Clears GSK's Nelkarmi, Second Asset from $10.6B Nuvalent Deal

  7. K-4971

    FDA Clears Roche's Wilserdly for Advanced Breast Cancer

  8. K-3717

    FDA Moves to Withdraw Approval of FloLipid Liquid Simvastatin

  9. C-7994

    FDA grants GSK accelerated approval for ALK inhibitor Nelkarmi

  10. K-8685

    FDA Clears Cosentyx for Polymyalgia Rheumatica, 11th US Indication

  11. P-1559

    FDA Hands Cipla's InvaGen New York Plant 'No Action Indicated' Status

Load older filings